Insulin icodec
Based on 1 Customer Validation
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95%
- CAS No.: 1188379-43-2
- Formule: C280H435N71O87S6
- Masse moléculaire:6380.26
-
Stockage:
Store at 4°C, do not freeze
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Insulin icodec (48 h at 37°C) is stable in rat, monkey, and human plasma (retaining ≥89.76% after 48 h at 37°C) but showed reduced stability in mouse plasma (82.89% retention after 48 h at 37°C)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BKS-db/db mice (male, 5-6 weeks old, 30-40 g, T2DM db/db model)[1]
-
Dosage:3 mg/kg; 6 mg/kg
-
Administration:s.c.; every two days; 52 days
-
Result:Showed similar blood glucose trend to TBE001-A-S033; reduced HbA1c levels by -7.96% (3 mg/kg) and -11.49% (6 mg/kg) relative to baseline.
Chemical Information
-
CAS No. 1188379-43-2
-
Appearance Liquid
-
Masse moléculaire 6380.26
-
Formule C280H435N71O87S6
-
Color Colorless to light yellow
-
Sequence
Chain1:Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-His-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-His-Tyr-Thr-Pro-{Lys(2OEG-γGlu-C20 diacid)} Chain2:Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-His-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-His-Tyr-Thr-Pro-Lys Chain3:{Ggu}-{Oaa}-{Oaa}(Disulfide:Chain1 Cys7-Chain2 Cys7, Disulfide:Chain1 Cys19-Chain2 Cys20, Disulfide:Chain 2 Cys6-Cys11, Amide bridge:Chain1 Lys29 to Chain3 ω-amino acid3)
-
Sequence Shortening
Chain1:FVNQHLCGSHLVEALHLVCGERGFHYTP-{Lys(2OEG-γGlu-C20 diacid)}; Chain2:GIVEQCCTSICSLEQLENYCN; Chain3:{Ggu}-{Oaa}-{Oaa} (Disulfide:Chain1 Cys7-Chain2 Cys7, Disulfide:Chain1 Cys19-Chain2 Cys20, Disulfide:Chain2 Cys6-Cys11, Amide bridge:Chain1 Lys29 to Chain3 ω-amino acid3)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Store at 4°C, do not freeze
Pureté et documentation
-
Fiche technique (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yu M, et al. Design of a novel long-acting insulin analogs by acetylation modification and compared with insulin Icodec. Sci Rep. 2025;15(1):9408. Published 2025 Mar 19. [Content Brief]
[2]. Lingvay I, et al. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care. 2021;44(7):1595-1603. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz